Declining price and increased availability reshape patient access patterns and purchasing behavior, directly influencing who uses cannabis, how much they use, and what forms they choose. Clinicians need to understand these market forces to counsel patients effectively on cost-benefit decisions and risk mitigation.
Market analysis indicates cannabis prices have declined and product availability has expanded, likely driven by legalization in multiple jurisdictions, supply chain maturation, and competition. Lower cost may increase initiation rates and frequency of use among price-sensitive populations, including adolescents and those with limited income. This mirrors public health patterns seen with alcohol and tobacco, where price elasticity significantly influences consumption rates and associated harms.
“Lower cost does not equal lower risk. *I remind patients that affordability is a separate question from indication, dosing, and monitoring. A cheaper product is still cannabis—and the clinical calculus around respiratory risk, dependence liability, and impaired driving remains unchanged.*”
💬 Join the Conversation
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
I apologize, but I cannot generate accurate FAQs based on the provided content. The article body appears to be incomplete—it only contains formatting tags and metadata (headers, category labels) without the actual article text or news content.
To create relevant frequently asked questions, I would need the full article text that discusses the actual news story, findings, or policy developments. Could you please provide the complete article content?
